Undetected coronavirus variant was in at least 15 countries before its discovery

A highly contagious SARS-CoV-2 variant was unknowingly spreading for months in the United States by October 2020, according to a new study from researchers with The University of Texas at Austin COVID-19 Modeling Consortium. Scientists first discovered it in early December in the United Kingdom, where the highly contagious and more lethal variant is thought to have originated. The journal Emerging Infectious Diseases, which has published an early-release version of the study, provides evidence that the coronavirus variant B117 (501Y) had spread across the globe undetected for months when scientists discovered it.

"By the time we learned about the U.K. variant in December, it was already silently spreading across the globe," said Lauren Ancel Meyers, the director of the COVID-19 Modeling Consortium at The University of Texas at Austin and a professor of integrative biology. "We estimate that the B117 variant probably arrived in the U.S. by October of 2020, two months before we knew it existed."

Analyzing data from 15 countries, researchers estimated the chance that travelers from the U.K. introduced the variant into 15 countries between Sept. 22 and Dec. 7, 2020. They found that the virus variant had almost certainly arrived in all 15 countries by mid-November. In the U.S., the variant probably had arrived by mid-October.

"This study highlights the importance of laboratory surveillance," Meyers said. "Rapid and extensive sequencing of virus samples is critical for early detection and tracking of new variants of concern."

In conjunction with the paper's publication, consortium members developed a new tool that decision-makers anywhere in the United States can use in planning for genetic sequencing that helps to detect the presence of variants. To help the U.S. expand national surveillance of variants, the new online calculator indicates the number of virus samples that must be sequenced in order to detect new variants when they first emerge. For example, if the goal is to detect an emerging variant by the time it is causing 1 out of every 1,000 new COVID-19 infections, approximately 3,000 SARS-CoV-2 positive specimens per week need to be sequenced.

"Health officials are looking for better ways to manage the unpredictability of this virus and future variants," said Spencer Woody, a postdoctoral fellow at the UT COVID-19 Modeling Consortium. "Our new calculator determines how many positive SARS-CoV-2 specimens must be sequenced to ensure that new threats are identified as soon as they start spreading."

He explained that the calculator has a second feature. "It also helps labs figure out how quickly they will detect new variants, given their current sequencing capacity."

"We created this tool to support federal, state and local health officials in building credible early warning systems for this and future pandemic threats," Meyers said.

Du Z, Wang L, Yang B, Ali ST, Tsang TK, Shan S, et al.
Risk for international importations of variant SARS-CoV-2 originating in the United Kingdom.
Emerg Infect Dis. 2021 doi: 10.3201/eid2705.210050

Most Popular Now

Johnson & Johnson announces advance purchase a…

Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ) (the Company), has entered into an agreement with the African Vacci...

Pfizer and BioNTech confirm high efficacy and no s…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced updated topline results from analysis of 927 confirmed symptomatic cases of COVID-19 observed in their pi...

Pfizer-BioNTech announce positive topline results …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that, in a Phase 3 trial in adolescents 12 to 15 years of age with or without prior evidence of SAR...

GSK to support manufacture of Novavax' COVID-19 va…

GSK has reached an agreement in principle with Novavax and the UK Government Vaccines Taskforce to support manufacturing of up to 60 million doses of Novavax' COVID-19 va...

Valneva reports positive Phase 1/2 data for its in…

Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical n...

Clinical trial completion rates decline during COV…

Social distancing and lockdowns may have reduced the spread of COVID-19, but researchers from Penn State College of Medicine also report those actions may have affected c...

BioNTech provides update on vaccine production sta…

BioNTech SE today announced that the European Medicines Agency (EMA) approved the manufacturing of the COVID-19 vaccine drug product at the facility in Marburg. As part o...

Pfizer and BioNTech request regulatory agencies ex…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today requested amendments to the U.S. Emergency Use Authorization (EUA) of the Pfizer-BioNTech vaccine (BNT162b2) ...

COVID-19 convalescent plasma with greater antibody…

Convalescent plasma, the use of survivors' antibodies transfused into sick COVID-19 patients is safe and significantly improves clinical outcomes when using high levels o...

COVID-19 causes 'unexpected' cellular response in …

New insights into the immune response to SARS-CoV-2 infections could bring better treatments for COVID-19 cases. An international team of researchers unexpectedly foun...

Study identifies possible COVID-19 drugs - includi…

A team led by scientists in the Perelman School of Medicine at the University of Pennsylvania has identified nine potential new COVID-19 treatments, including three that ...

Undetected coronavirus variant was in at least 15 …

A highly contagious SARS-CoV-2 variant was unknowingly spreading for months in the United States by October 2020, according to a new study from researchers with The Unive...